drugset / Trial / NCT02524054

Aerosol Inhalation Treatment for Dyspnea - Patients

NCT02524054

RandomizedCrossoverDouble-blindSupportive care

Summary

The purpose of this protocol is to develop and test aerosol furosemide, as a treatment that has the potential to significantly improve symptom management and enhance the quality of care for patients with intractable dyspnea.

Timeline

Start
2014-11-01
Primary completion
2016-11-30
Completion
2017-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Furosemide Other / unclassified 40 mg Inhaled
Subject Furosemide Other / unclassified 80 mg Inhaled

Indications

No indication recorded.